LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3799 | 4168 | 0.9126 | 0.8870 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4468 | 4245 | 1.0545 | 1.0693 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3851 | 4168 | 0.9256 | 0.9033 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4307 | 4245 | 1.0149 | 1.0187 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 3837 | 4168 | 0.9229 | 0.8986 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3745 | 4245 | 0.8833 | 0.8513 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3339 | 4168 | 0.8022 | 0.7380 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3019 | 4245 | 0.7092 | 0.6096 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2483 | 4168 | 0.5965 | 0.4379 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP5 | 72 | hr | 1401 | 1770 | 4245 | 0.4159 | 0.1523 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP6 | 72 | hr | 1401 | 900 | 4168 | 0.2163 | -0.2482 |
| SK-BR-3 | Tozasertib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 1337 | 4245 | 0.3153 | -0.0303 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 1312 | 4245 | 0.3094 | -0.0416 |
| SK-BR-3 | Tozasertib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1448 | 4245 | 0.3417 | 0.0198 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1451 | 4245 | 0.3428 | 0.0220 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1428 | 4245 | 0.3376 | 0.0123 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 72 | hr | 1401 | 1562 | 4245 | 0.3690 | 0.0702 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4418 | 4168 | 1.0591 | 1.0734 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4559 | 4168 | 1.0934 | 1.1167 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4499 | 4168 | 1.0796 | 1.0996 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4581 | 4168 | 1.0994 | 1.1246 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4459 | 4168 | 1.0699 | 1.0881 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 72 | hr | 1401 | 4258 | 4168 | 1.0210 | 1.0261 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4262 | 4168 | 1.0220 | 1.0271 |
| SK-BR-3 | NVP-TAE684 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4201 | 4168 | 1.0079 | 1.0101 |